Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-PanTumor03: Datopotamab deruxtecan in advanced/metastatic solid tumours
2022-000776-19Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Aug 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of datopotamab deruxtecan in Nonhematologic neoplasms (5 arms), sponsored by AstraZeneca. Primary endpoint: Objective response rate. Started Aug 2022; status: active.
02
Drugs
datopotamab deruxtecan
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2022-000776-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000776-19.